Polyneuron Pharmaceuticals Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Out of Business

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Liquidation

Polyneuron Pharmaceuticals General Information

Description

Developer of novel therapeutics intended to facilitate the treatment of antibody-mediated autoimmune diseases. The company's biodegradable glycopolymers-based therapeutics selectively eliminate the pathological autoantibodies, while leaving the rest of the immune system intact, enabling medical practitioners to treat patients with immune disorders safely and effectively.

Contact Information

Website
www.polyneuron.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Hochbergerstrasse 60C
  • 4057 Basel
  • Switzerland
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Life Sciences
Corporate Office
  • Hochbergerstrasse 60C
  • 4057 Basel
  • Switzerland

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Polyneuron Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Bankruptcy: Liquidation Completed Bankruptcy: Liquidation
11. Grant 14-Apr-2021 Completed Generating Revenue
10. Later Stage VC (Series A) 28-Aug-2020 Completed Pre-Clinical Trials
9. Seed Round 14-May-2018 Completed Pre-Clinical Trials
8. Accelerator/Incubator 18-Sep-2017 Completed Pre-Clinical Trials
7. Grant 31-Aug-2017 Completed Pre-Clinical Trials
6. Seed Round 12-May-2016 Completed Pre-Clinical Trials
5. Grant 05-May-2016 Completed Pre-Clinical Trials
4. Accelerator/Incubator 15-Jul-2015 $3.35K $153K Completed Startup
3. Accelerator/Incubator 02-Jun-2015 $150K $150K Completed Pre-Clinical Trials
To view Polyneuron Pharmaceuticals’s complete valuation and funding history, request access »

Polyneuron Pharmaceuticals Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series Seed
To view Polyneuron Pharmaceuticals’s complete cap table history, request access »

Polyneuron Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel therapeutics intended to facilitate the treatment of antibody-mediated autoimmune diseases. The compa
Drug Discovery
Basel, Switzerland
9 As of 2022

Gothenburg, Sweden
 

Cambridge, MA
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Polyneuron Pharmaceuticals Competitors (40)

One of Polyneuron Pharmaceuticals’s 40 competitors is Toleranzia, a Formerly VC-backed company based in Gothenburg, Sweden.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Toleranzia Formerly VC-backed Gothenburg, Sweden
AnTolRx Formerly VC-backed Cambridge, MA
ImmunOs Therapeutics Venture Capital-Backed Schlieren, Switzerland
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA
Anokion Venture Capital-Backed Ecublens, Switzerland
You’re viewing 5 of 40 competitors. Get the full list »

Polyneuron Pharmaceuticals Patents

  • 4

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • Pending

  • Expiring in next 12 mo

Polyneuron Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3056206-A1 Glycopolymers sequestering carbohydrate-binding proteins Inactive 15-Mar-2017
US-20200079808-A1 Glycopolymers sequestering carbohydrate-binding proteins Inactive 15-Mar-2017
AU-2018235063-A1 Glycopolymers sequestering carbohydrate-binding proteins Inactive 15-Mar-2017
EP-3595730-A1 Glycopolymers sequestering carbohydrate-binding proteins Inactive 15-Mar-2017 C07H15/12

Polyneuron Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

Polyneuron Pharmaceuticals FAQs

  • When was Polyneuron Pharmaceuticals founded?

    Polyneuron Pharmaceuticals was founded in 2014.

  • Where is Polyneuron Pharmaceuticals headquartered?

    Polyneuron Pharmaceuticals is headquartered in Basel, Switzerland.

  • What is the size of Polyneuron Pharmaceuticals?

    Polyneuron Pharmaceuticals has 9 total employees.

  • What industry is Polyneuron Pharmaceuticals in?

    Polyneuron Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Polyneuron Pharmaceuticals a private or public company?

    Polyneuron Pharmaceuticals is a Private company.

  • What is Polyneuron Pharmaceuticals’s current revenue?

    The current revenue for Polyneuron Pharmaceuticals is .

  • How much funding has Polyneuron Pharmaceuticals raised over time?

    Polyneuron Pharmaceuticals has raised $46.5M.

  • Who are Polyneuron Pharmaceuticals’s competitors?

    Toleranzia, AnTolRx, ImmunOs Therapeutics, Alnylam Pharmaceuticals, and Anokion are some of the 40 competitors of Polyneuron Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »